Abstract
A series of imidazo[1,2-b]thiazole derivatives is shown to activate the NAD(+)-dependent deacetylase SIRT1, a potential new therapeutic target to treat various metabolic disorders. This series of compounds was derived from a high throughput screening hit bearing an oxazolopyridine core. Water-solubilizing groups could be installed conveniently at either the C-2 or C-3 position of the imidazo[1,2-b]thiazole ring. The SIRT1 enzyme activity could be adjusted by modifying the amide portion of these imidazo[1,2-b]thiazole derivatives. The most potent analogue within this series, namely, compound 29, has demonstrated oral antidiabetic activity in the ob/ob mouse model, the diet-induced obesity (DIO) mouse model, and the Zucker fa/fa rat model.
MeSH terms
-
Animals
-
Diabetes Mellitus, Experimental / drug therapy
-
Diabetes Mellitus, Type 2 / drug therapy
-
Enzyme Activators / chemical synthesis*
-
Enzyme Activators / chemistry
-
Enzyme Activators / pharmacology
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Imidazoles / chemical synthesis*
-
Imidazoles / chemistry
-
Imidazoles / pharmacology
-
Mice
-
Quinoxalines / chemical synthesis*
-
Quinoxalines / chemistry
-
Quinoxalines / pharmacology
-
Rats
-
Rats, Zucker
-
Sirtuin 1 / metabolism*
-
Structure-Activity Relationship
-
Thiazoles / chemical synthesis*
-
Thiazoles / chemistry
-
Thiazoles / pharmacology
Substances
-
Enzyme Activators
-
Hypoglycemic Agents
-
Imidazoles
-
N-(2-(3-(piperazin-1-ylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
-
Quinoxalines
-
Thiazoles
-
Sirt1 protein, mouse
-
Sirt1 protein, rat
-
Sirtuin 1